Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International Inc. (NYSE:BAX) will conduct a conference call on February 17, 2022, at 7:30 a.m. Central Time, to discuss its fourth-quarter 2021 financial results. Interested participants can pre-register via the provided link. This call will also be webcast on Baxter's website. Baxter provides a wide range of medical products and services in over 100 countries, focusing on critical care, kidney care, and surgical products. The company aims to leverage its legacy to drive innovation in healthcare.
Baxter International Inc. (NYSE:BAX) has completed its acquisition of Hillrom for $10.5 billion, paying $156 per share in cash. This transaction aims to enhance Baxter's healthcare transformation vision and is expected to generate approximately $250 million in annual pre-tax cost synergies by the end of year three. The acquisition is projected to positively impact Baxter's adjusted earnings per share, expanding margins and cash flow generation, with high single-digit returns on invested capital anticipated by year five. The combination will also enhance product accessibility globally.
Baxter International Inc. (NYSE:BAX) announced findings from a study suggesting that machine learning and AI can enhance medication safety in hospitals. Conducted with MedAware, the research analyzed over 3.8 million infusions and found that AI could assist in adjusting Dose Error Reduction Systems (DERS) to reduce medication errors. The results indicated that 52% of outliers triggered hard limits, showcasing the need for better DERS limits. The study was presented at the ASHP 2021 Midyear Clinical Meeting, highlighting advancements in infusion pump technology for patient safety.
Summary not available.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on January 3, 2022, to shareholders recorded as of December 3, 2021. This dividend reflects an annual rate of $1.12 per share. The announcement emphasizes the company's commitment to returning value to its shareholders through consistent dividend payments.
Summary not available.
Baxter International Inc. (NYSE:BAX) has announced a significant investment of approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This expansion will enhance production capabilities with a new syringe filling line and increased vial capacity, aimed at improving product stability and shelf life via lyophilization. The construction is set to start in 2022 and be completed by 2024, positioning Baxter to meet rising demand for injectable pharmaceuticals across Europe and the United States.
Baxter International Inc. (NYSE:BAX) presented new findings at the American Society of Nephrology’s Kidney Week, indicating that patients using the Sharesource remote patient management platform for automated peritoneal dialysis (APD) experienced nearly double the survival rates compared to those using conventional methods. This study, involving 815 kidney patients across 22 hospitals in Mexico, suggests that digital health solutions can significantly enhance clinical outcomes, reducing hospital visits during the COVID-19 pandemic.
Baxter International Inc. (NYSE:BAX) will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Chief Financial Officer Jay Saccaro is set to speak at 9:40 a.m. Eastern Time. Investors and the public can access the live webcast of the presentation through www.baxter.com, which will also be available for replay until May 21, 2022. Baxter continues to innovate in medical products, impacting patients and healthcare providers globally.
Baxter International reported a 9% increase in third-quarter revenue, reaching $3.2 billion, driven by strong sales across all geographic segments. U.S. GAAP earnings per share rose 29% to $0.89, while adjusted EPS increased by 23% to $1.02. Baxter anticipates full-year sales growth of 7%-8% and adjusted EPS between $3.58 and $3.62. The company announced the acquisition of Hillrom, aiming to enhance its product portfolio and innovation pipeline. Additionally, Baxter launched new medical products and received FDA approval for premix Norepinephrine Bitartrate injection.